drugset
drugset / Trial / NCT02212925

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

NCT02212925 ↗

Phase 1 Terminated 38 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 14332 CL following administration of multiple rising oral doses over 10 days in patients with type 2 diabetes.

Timeline

Start
2006-11
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 14332 CL Unknown 0.5 mg Oral
Subject BI 14332 CL Unknown 2.5 mg Oral
Subject BI 14332 CL Unknown 5 mg Oral
Subject BI 14332 CL Unknown 10 mg Oral
Subject BI 14332 CL Unknown 20 mg Oral

Indications

type 2 diabetes mellitus